Elagolix, (Figure 3), is a small molecule compound that is a first-in-class GnRH receptor antagonist approved for the treatment of moderate or severe pain associated with endometriosis [88,89]
Obesity, one of the most common clinical phenotypes of HFpEF, is specifically and independently associated with the disease, and it often manifests unique clinical and haemodynamic features in individuals [6]
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis
In vitro studies have shown that three times the potency of benzbromarone and 100 times of probenecid effectiveness (Yue et al., 2019)
164 ShimamuraM.SatoN.OshimaK.AokiM.KurinamiH.WaguriS.et al (2004)
DSIP flux across the BMEC monolayers was also found to be bidirectional, insensitive to metabolic inhibitors, and not altered by high concentrations of tryptophan